We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions Segment, Analytical Instruments, and Specialty Diagnostics.
- Recent TMO Stock Price: $565.64
- Yearly Gain for TMO stock: -10.29%
- Market Cap for TMO stock: $216.95B
- P/E Ratio for TMO stock: 31.109
Will TMO's stock price go up? Is there an accurate TMO stock forecast available?
TipRanks.com reports that Thermo Fisher currently has 13 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $614.40. The target pricing ranges from a high TMO forecast of $690.00 down to a low forecast of $505.00. Thermo Fisher (TMO)’s last closing stock price was $565.64 which would put the average price target at 8.62% upside.
In addition, TradingView issued a Strong Buy rating for TMO stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on TMO stock.
Other analysts covering TMO include:
- Justin Bowers of Deutsche Bank issued a Buy rating with the price target of $ 620 on 3 weeks ago
- Daniel Brennan of Cowen & Co. issued a Buy rating with the price target of $ 690 on 3 weeks ago
- Conor McNamara of RBC Capital issued a Buy rating with the price target of $ 661 on 4 weeks ago
- Luke Sergott of Barclays issued a Buy rating with the price target of $ 570 on 1 month ago
If you are wondering if TMO is a good stock to buy, here are 3rd party ratings for TMO stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 40% (99 out of 250)
What is the sentiment on the street regarding Thermo Fisher? (Current ratings compiled by TipRanks.com)
- News Sentiment for TMO stock: Very Bullish
- Blogger Consensus for TMO stock: Bullish
- Media Buzz for TMO stock: Medium
- Insider Signal for TMO stock: Negative
- Investor Sentiment for TMO stock: ―
- Hedge Fund signal for TMO stock: Negative
The stock market is extremely volatile, and you need to do your own research on TMO stock including scouring the social networks like TMO StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for TMO stock chart >>
Summary: Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.
- Recent ABT Stock Price: $111.77
- Yearly Gain for ABT stock: -17.94%
- Market Cap for ABT stock: $191.06B
- P/E Ratio for ABT stock: 24.714
Will ABT's stock price go up? Is there an accurate ABT stock forecast available?
TipRanks.com reports that Abbott Labs currently has 13 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $118.62. The target pricing ranges from a high ABT forecast of $140.00 down to a low forecast of $105.00. Abbott Labs (ABT)’s last closing stock price was $111.77 which would put the average price target at 6.13% upside.
In addition, TradingView issued a Strong Buy rating for ABT stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ABT stock.
Other analysts covering ABT include:
- Josh Jennings of Cowen & Co. issued a Buy rating with the price target of $ 130 on 3 weeks ago
- Joanne Wuensch of Citigroup issued a Buy rating with the price target of $ 125 on 3 weeks ago
- Shagun Singh Chadha of RBC Capital issued a Buy rating with the price target of $ 126 on 2 months ago
- Anthony Petrone of Mizuho Securities issued a Hold rating with the price target of $ 105 on 2 months ago
If you are wondering if ABT is a good stock to buy, here are 3rd party ratings for ABT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Bottom 40% (150 out of 250)
What is the sentiment on the street regarding Abbott Labs? (Current ratings compiled by TipRanks.com)
- News Sentiment for ABT stock: Very Bullish
- Blogger Consensus for ABT stock: Bullish
- Media Buzz for ABT stock: Very Low
- Insider Signal for ABT stock: ―
- Investor Sentiment for ABT stock: ―
- Hedge Fund signal for ABT stock: Negative
The stock market is extremely volatile, and you need to do your own research on ABT stock including scouring the social networks like ABT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ABT stock chart >>
Summary: HCA Healthcare, Inc.'is the largest non-governmental operator of acute care hospitals in the U.S. The company operates hospitals and related health care entities. The general, acute care hospitals also provide outpatient services such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology and physical therapy. It operates in two geographically organized groups - the National and American Groups. The National Group includes hospitals across Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire,'North Carolina, South Carolina, Utah and Virginia. The American Group includes hospitals across Colorado, northern Georgia, Kansas, southern Kentucky, Louisiana, Missouri, Tennessee and Texas. The company also operates hospitals in England that are included in the Corporate and Other group. The company's general, acute care hospitals provide a wide range of services to cater to different medical specialties.
- Recent HCA Stock Price: $246.58
- Yearly Gain for HCA stock: -5.59%
- Market Cap for HCA stock: $68.76B
- P/E Ratio for HCA stock: 13.735
Will HCA's stock price go up? Is there an accurate HCA stock forecast available?
TipRanks.com reports that HCA Healthcare currently has 15 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $250.73. The target pricing ranges from a high HCA forecast of $286.00 down to a low forecast of $220.00. HCA Healthcare (HCA)’s last closing stock price was $246.58 which would put the average price target at 1.68% upside.
In addition, TradingView issued a n/a (possibly response change) rating for HCA stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on HCA stock.
Other analysts covering HCA include:
- Steve Baxter of Wells Fargo issued a Hold rating with the price target of $ 243 on 1 day ago
- Pito Chickering of Deutsche Bank issued a Buy rating with the price target of $ 275 on 1 day ago
- Whit Mayo of SVB Securities issued a Buy rating with the price target of $ 286 on 2 weeks ago
- Ann Hynes of Mizuho Securities issued a Buy rating with the price target of $ 265 on 3 weeks ago
If you are wondering if HCA is a good stock to buy, here are 3rd party ratings for HCA stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 13% (218 out of 250)
What is the sentiment on the street regarding HCA Healthcare? (Current ratings compiled by TipRanks.com)
- News Sentiment for HCA stock: Very Bullish
- Blogger Consensus for HCA stock: Bullish
- Media Buzz for HCA stock: Very Low
- Insider Signal for HCA stock: Negative
- Investor Sentiment for HCA stock: ―
- Hedge Fund signal for HCA stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on HCA stock including scouring the social networks like HCA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for HCA stock chart >>
Summary: DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of DexCom's monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. The company's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels.
- Recent DXCM Stock Price: $115.04
- Yearly Gain for DXCM stock: -10.42%
- Market Cap for DXCM stock: $44.32B
- P/E Ratio for DXCM stock: 207.731
Will DXCM's stock price go up? Is there an accurate DXCM stock forecast available?
TipRanks.com reports that Dexcom currently has 12 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $127.42. The target pricing ranges from a high DXCM forecast of $150.00 down to a low forecast of $103.00. Dexcom (DXCM)’s last closing stock price was $115.04 which would put the average price target at 10.76% upside.
In addition, TradingView issued a n/a (possibly response change) rating for DXCM stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on DXCM stock.
Other analysts covering DXCM include:
- Jeff Johnson of Robert W. Baird issued a Buy rating with the price target of $ 130 on 2 weeks ago
- Matthew O'Brien of Piper Sandler issued a Buy rating with the price target of $ 150 on 2 weeks ago
- Joanne Wuensch of Citigroup issued a Buy rating with the price target of $ 146 on 3 weeks ago
- Marie Thibault of BTIG issued a Buy rating with the price target of $ 126 on 3 weeks ago
If you are wondering if DXCM is a good stock to buy, here are 3rd party ratings for DXCM stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 40% (99 out of 250)
What is the sentiment on the street regarding Dexcom? (Current ratings compiled by TipRanks.com)
- News Sentiment for DXCM stock: Very Bullish
- Blogger Consensus for DXCM stock: Bullish
- Media Buzz for DXCM stock: Low
- Insider Signal for DXCM stock: ―
- Investor Sentiment for DXCM stock: ―
- Hedge Fund signal for DXCM stock: Negative
The stock market is extremely volatile, and you need to do your own research on DXCM stock including scouring the social networks like DXCM StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for DXCM stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================